Mural Oncology plc (MURA)
NASDAQ: MURA · Real-Time Price · USD
2.500
+0.010 (0.40%)
Jul 18, 2025, 4:00 PM - Market closed
Company Description
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Mural Oncology plc
| Country | Ireland |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Caroline Loew |
Contact Details
Address: 10 Earlsfort Terrace Dublin, D02 T380 Ireland | |
| Phone | 353 1 905 8020 |
| Website | muraloncology.com |
Stock Details
| Ticker Symbol | MURA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001971543 |
| ISIN Number | IE000LK2BOB4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Caroline J. Loew Ph.D. | President, Chief Executive Officer and Director |
| Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
| Maiken Keson-Brookes | Chief Legal Officer |
| Justin Levine | Head of Human Resources and Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2025 | 144 | Filing |
| Jun 26, 2025 | SCHEDULE 13G | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |